Regeneron Pharmaceuticals (REGN) has emerged as the successful bidder in the bankruptcy auction for most of the assets of 23andMe Holding Co., a prominent player in human genetics and biotechnology.REGN plans to acquire 23andMe’s Personal Genome Service, Total Health and Research Services business units, Biobank and related assets in a transaction valued at $256 million. Consequently, 23andMe will operate as a wholly-owned subsidiary of Regeneron Pharmaceuticals. The impending purchase, however, does not in ...